ClinicalTrials.gg

Program

QLM3003

A development code. Also written as “1.5% QLM3003 ointment”, “2% QLM3003 ointment” and “1.5% QLM3003”.

Its studies are mostly in Dermatitis, Atopic, led by Qilu Pharmaceutical.

Furthest: phase 3, since Mar 11, 20253 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical31 open or runningphase 3since Mar 11, 2025Jun 22, 2023Mar 2027phase 3 · NCT06880276

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2023First study: phase 1 study in Dermatitis, AtopicFirst studyNCT05932888 · 40 enrolled · China
  2. Sep 21, 2023Phase 2 study in Dermatitis, AtopicNCT06058000 · 120 enrolled · China
  3. Mar 11, 2025Phase 3 study in Dermatitis, AtopicNCT06880276 · 360 planned · China

Ahead

  1. Mar 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06880276

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06880276Dermatitis, Atopic · China3RecruitingMar 2027360
NCT06058000Dermatitis, Atopic · China2CompletedSep 2, 2024120
NCT05932888Dermatitis, Atopic · China1CompletedAug 5, 202340

How it is read

Names in the registry

  • “1.5% QLM3003 ointment”, 1 entry
  • “2% QLM3003 ointment”, 1 entry
  • “1.5% QLM3003”, 1 entry
  • “2% QLM3003”, 1 entry
  • “QLM3003”, 1 entry

Codes read as this program: QLM3003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.